AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28107598 — intervention group
Group type: EXPERIMENTAL
Intervention: Odds of dropout related to negative urine screens
Number of subjects: 440
Study 28107598 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention time related to negative urine screens
Number of subjects: 440
Study 25873090 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) with booster sessions
Number of subjects: 0
Study 25873090 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 25873090 — intervention group
Group type: COMPARATOR
Intervention: Waiting group (control)
Number of subjects: 0
Study 23692061 — intervention group
Group type: EXPERIMENTAL
Intervention: PA32540 (EC-ASA 325 mg + IR-omeprazole 40 mg)
Number of subjects: 26
Study 23692061 — intervention group
Group type: COMPARATOR
Intervention: Enteric-coated omeprazole 40 mg
Number of subjects: 26
Study 22260148 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help manual along with standard care and treatment
Number of subjects: 56
Study 22260148 — intervention group
Group type: COMPARATOR
Intervention: Standard care and treatment
Number of subjects: 56
Study 20628129 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralized telecare management by a nurse-physician specialist team with automated home-based symptom monitoring (IVR or Internet)
Number of subjects: 405
Study 20628129 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 405
Study 17587390 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg daily in week 1, 500 mg twice daily in week 2, 1000 mg twice daily in weeks 3 and 4)
Number of subjects: 21
Study 17587390 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 21
Study 16138267 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone 45 mg
Number of subjects: 173
Study 16138267 — intervention group
Group type: COMPARATOR
Intervention: glimepiride 1-6 mg
Number of subjects: 173
Study 11895158 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids
Number of subjects: 0
Study 11895158 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 9861542 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (E) infusion (15 ng/kg/hr)
Number of subjects: 19
Study 9861542 — intervention group
Group type: COMPARATOR
Intervention: Vehicle infusion
Number of subjects: 19
Study 8706118 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ibuprofen
Number of subjects: 95
Study 8706118 — intervention group
Group type: COMPARATOR
Intervention: 500 mg acetylsalicylic acid
Number of subjects: 95
Study 8706118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 2693355 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed reduction and internal fixation with a sliding compression screwplate
Number of subjects: 278
Study 2693355 — intervention group
Group type: EXPERIMENTAL
Intervention: Moore hemiarthroplasty
Number of subjects: 278
Study 2693355 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip replacement with a Howse semicaptive prosthesis
Number of subjects: 278
Study 2693355 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 278
Study 44669 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (0.5 microgram)
Number of subjects: 8
Study 44669 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (2 microgram)
Number of subjects: 8
Study 44669 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (2 ng - 2 microgram)
Number of subjects: 8
Study 44669 — intervention group
Group type: COMPARATOR
Intervention: Control (no terbutaline)
Number of subjects: 8
Study 31154431 — intervention group
Group type: EXPERIMENTAL
Intervention: High LV mass-wall stress-heart rate product
Number of subjects: 1522
Study 30938637 — intervention group
Group type: EXPERIMENTAL
Intervention: 250F-TMPnano dentifrice (250-ppm fluoride plus 0.05% nanosized TMP)
Number of subjects: 19
Study 30938637 — intervention group
Group type: COMPARATOR
Intervention: 1,100F dentifrice (1,100-ppm fluoride)
Number of subjects: 19
Study 30938637 — intervention group
Group type: COMPARATOR
Intervention: 250F dentifrice (250-ppm fluoride)
Number of subjects: 19
Study 30938637 — intervention group
Group type: COMPARATOR
Intervention: Placebo (without F/TMP)
Number of subjects: 19
Study 25881623 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid response hospice at home service
Number of subjects: 953
Study 25881623 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 953
Study 23422946 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropicamide 0.5% before refraction and visual acuity assessment
Number of subjects: 316
Study 23422946 — intervention group
Group type: COMPARATOR
Intervention: Tropicamide 0.5% after refraction and visual acuity assessment
Number of subjects: 316
Study 21067866 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in estradiol concentrations
Number of subjects: 0
Study 21067866 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing session during fertile window
Number of subjects: 0
Study 21067866 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in estradiol from outside to inside the fertile window
Number of subjects: 0
Study 21067866 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial cues of high testosterone
Number of subjects: 0
Study 19808156 — intervention group
Group type: EXPERIMENTAL
Intervention: Video decision support tool after verbal narrative
Number of subjects: 14
Study 19808156 — intervention group
Group type: COMPARATOR
Intervention: Verbal narrative
Number of subjects: 14
Study 16416218 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole, amoxicillin, and clarithromycin
Number of subjects: 91
Study 16416218 — intervention group
Group type: COMPARATOR
Intervention: lansoprazole and placebo
Number of subjects: 91
Study 15120943 — intervention group
Group type: COMPARATOR
Intervention: Standard arm of uniform treatment, 10% of patients from each participating trial.
Number of subjects: 0
Study 15120943 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront randomization and assessment of prognostic profiles.
Number of subjects: 0
Study 15120943 — intervention group
Group type: EXPERIMENTAL
Intervention: Intent-to-treat evaluation and shared protocol standards.
Number of subjects: 0
Study 11743703 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D video glasses
Number of subjects: 23
Study 11743703 — intervention group
Group type: COMPARATOR
Intervention: Control situation (without video glasses)
Number of subjects: 23
Study 9260123 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor embryo pregnancies
Number of subjects: 67
Study 9260123 — intervention group
Group type: COMPARATOR
Intervention: Standard IVF pregnancies
Number of subjects: 67
Study 8508349 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil and cisplatin (FP)
Number of subjects: 295
Study 8508349 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil, doxorubicin, and mitomycin C (FAM)
Number of subjects: 295
Study 8508349 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil alone (FU)
Number of subjects: 295
Study 8508349 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 295
Study 2961501 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.1 mg
Number of subjects: 48
Study 2961501 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.32 mg
Number of subjects: 48
Study 2961501 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 1.0 mg
Number of subjects: 48
Study 2961501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 30318424 — intervention group
Group type: EXPERIMENTAL
Intervention: Buzzy application
Number of subjects: 65
Study 30318424 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Buzzy application)
Number of subjects: 65
Study 27370062 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 46
Study 27370062 — intervention group
Group type: COMPARATOR
Intervention: Standard Drug Treatment (ST)
Number of subjects: 46
Study 27370062 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Treatment (CBT + ST)
Number of subjects: 46
Study 24232127 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 5
Study 22509402 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-based NRT dosing
Number of subjects: 633
Study 22509402 — intervention group
Group type: COMPARATOR
Intervention: Phenotype-based NRT dosing
Number of subjects: 633
Study 20302678 — intervention group
Group type: EXPERIMENTAL
Intervention: Online GAD intervention (E-couch) with human support (telephone calls)
Number of subjects: 0
Study 20302678 — intervention group
Group type: EXPERIMENTAL
Intervention: Online GAD intervention (E-couch) with automated support (emails)
Number of subjects: 0
Study 20302678 — intervention group
Group type: COMPARATOR
Intervention: Non-active intervention arms
Number of subjects: 0
Study 18593081 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline nasal irrigation (HSNI)
Number of subjects: 28
Study 16222065 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients
Number of subjects: 509
Study 16222065 — intervention group
Group type: COMPARATOR
Intervention: Non-obese patients
Number of subjects: 509
Study 12393308 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (TCA)
Number of subjects: 52
Study 12393308 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (SSRI)
Number of subjects: 52
Study 12393308 — intervention group
Group type: COMPARATOR
Intervention: Unmedicated patients
Number of subjects: 52
Study 10432886 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced sputum collection
Number of subjects: 107
Study 10432886 — intervention group
Group type: COMPARATOR
Intervention: Sputum collected at home
Number of subjects: 107
Study 7480228 — intervention group
Group type: EXPERIMENTAL
Intervention: Textured devices irrigated with Betadine
Number of subjects: 60
Study 7480228 — intervention group
Group type: COMPARATOR
Intervention: Smooth devices irrigated with saline solution
Number of subjects: 60
Study 7480228 — intervention group
Group type: EXPERIMENTAL
Intervention: Betadine-irrigated devices
Number of subjects: 60
Study 7480228 — intervention group
Group type: EXPERIMENTAL
Intervention: Textured-surface devices
Number of subjects: 60
Study 1705432 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerulein at doses of 0.05, 0.1, 0.2, 0.3, 0.5 microgram/Kg/h
Number of subjects: 25
Study 1705432 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (125 ml/h)
Number of subjects: 25
Study 1705432 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerulein (various doses)
Number of subjects: 25
Study 7211531 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent reinforcement for morphine-free urinalysis results
Number of subjects: 7
Study 7211531 — intervention group
Group type: COMPARATOR
Intervention: Non-reinforcement weeks
Number of subjects: 7
Study 7211531 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-study period
Number of subjects: 7
Study 31892662 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (two oral boluses of 100,000 IU vitamin D3 with 400 IU vitamin D3 daily)
Number of subjects: 865
Study 31892662 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical placebo boluses with daily placebo)
Number of subjects: 865
Study 31892662 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 865
Study 31892662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 865
Study 28698999 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based tailored intervention (Cancer Aftercare Guide)
Number of subjects: 462
Study 28698999 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait-list)
Number of subjects: 462
Study 26012120 — intervention group
Group type: EXPERIMENTAL
Intervention: Superelastic NiTi archwires
Number of subjects: 189
Study 26012120 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat activated NiTi archwires
Number of subjects: 189
Study 26012120 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 189
Study 24456624 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A: 25μg/inoculation
Number of subjects: 24
Study 24456624 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B: 100μg/inoculation
Number of subjects: 24
Study 24456624 — intervention group
Group type: COMPARATOR
Intervention: Arm C: Control group (no injections)
Number of subjects: 24
Study 22704461 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 220 mg once daily
Number of subjects: 0
Study 22704461 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg once daily
Number of subjects: 0
Study 22704461 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 0
Study 19854395 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs published in CONSORT-endorsing journals
Number of subjects: 42
Study 19854395 — intervention group
Group type: COMPARATOR
Intervention: RCTs published in nonendorsing journals
Number of subjects: 42
Study 19854395 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic methodologic criteria reporting
Number of subjects: 42
Study 19854395 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse-event-related criteria reporting
Number of subjects: 42
Study 19854395 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific nonpharmacologic criteria reporting
Number of subjects: 42
Study 15834756 — intervention group
Group type: EXPERIMENTAL
Intervention: GLV with more oil (100 g GLV/day + 5 g oil/day)
Number of subjects: 40
Study 15834756 — intervention group
Group type: EXPERIMENTAL
Intervention: GLV with vitamin E (100 mg/day)
Number of subjects: 40
Study 15834756 — intervention group
Group type: COMPARATOR
Intervention: Beta-carotene without GLV (10 mg/day)
Number of subjects: 40
Study 12504142 — intervention group
Group type: EXPERIMENTAL
Intervention: Test option 200 N and 0.15 m/s
Number of subjects: 8
Study 12504142 — intervention group
Group type: EXPERIMENTAL
Intervention: Test option 200 N and 0.30 m/s
Number of subjects: 8
Study 12504142 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional friction measurement
Number of subjects: 8
Study 12504142 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum friction coefficient
Number of subjects: 8
Study 12504142 — intervention group
Group type: EXPERIMENTAL
Intervention: Limit for preventing a slip
Number of subjects: 8
Study 11593611 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion of fresh whole blood
Number of subjects: 238
Study 11593611 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional herb medicines
Number of subjects: 238
Study 11593611 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic observation of hemorrheologic changes
Number of subjects: 238
Study 8532025 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of epoprostenol
Number of subjects: 81
Study 8532025 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 81
Study 1676368 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day tertatolol (T)
Number of subjects: 0
Study 1676368 — intervention group
Group type: COMPARATOR
Intervention: 80 mg/day nadolol (N)
Number of subjects: 0
Study 6344196 — intervention group
Group type: EXPERIMENTAL
Intervention: Griseofulvin treatment
Number of subjects: 39
Study 6344196 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 39
Study 31311097 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclined bench press at 12% of 1 repetition maximum
Number of subjects: 12
Study 31311097 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclined bench press at 24% of 1 repetition maximum
Number of subjects: 12
Study 31311097 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg extension exercise at 12% of 1 repetition maximum
Number of subjects: 12
Study 31311097 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg extension exercise at 24% of 1 repetition maximum
Number of subjects: 12
Study 30154493 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular sutures
Number of subjects: 376
Study 30154493 — intervention group
Group type: COMPARATOR
Intervention: Staples
Number of subjects: 376
Study 26411813 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) to the left lower extremity using a blood pressure cuff
Number of subjects: 0
Study 26411813 — intervention group
Group type: COMPARATOR
Intervention: Control group (cuff applied but not inflated or deflated)
Number of subjects: 0
Study 26411813 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 0
Study 26411813 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 24462484 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50g/kg alcohol
Number of subjects: 28
Study 24462484 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.57mL/kg ED
Number of subjects: 28
Study 24462484 — intervention group
Group type: EXPERIMENTAL
Intervention: AmED
Number of subjects: 28
Study 24462484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 24462484 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 28
Study 24462484 — intervention group
Group type: EXPERIMENTAL
Intervention: ED
Number of subjects: 28
Study 22186668 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion
Number of subjects: 0
Study 22186668 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbidopa‐levodopa administration
Number of subjects: 0
Study 20629547 — intervention group
Group type: EXPERIMENTAL
Intervention: Puros Dermis (PDM)
Number of subjects: 14
Study 20629547 — intervention group
Group type: EXPERIMENTAL
Intervention: Alloderm (ADM)
Number of subjects: 14
Study 17574929 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day, n=25)
Number of subjects: 51
Study 17574929 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=26)
Number of subjects: 51
Study 16359281 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured 8-week educational telephone intervention
Number of subjects: 168
Study 16359281 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 168
Study 12412495 — intervention group
Group type: EXPERIMENTAL
Intervention: Case version under time pressure
Number of subjects: 0
Study 12412495 — intervention group
Group type: EXPERIMENTAL
Intervention: Case version under no time pressure
Number of subjects: 0
Study 12412495 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-plaintiff beliefs
Number of subjects: 0
Study 12412495 — intervention group
Group type: COMPARATOR
Intervention: Pro-defendant beliefs
Number of subjects: 0
Study 9674467 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (maximum dose, 0.05 mg/kg/min)
Number of subjects: 17
Study 9674467 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P (maximum dose, 100 pmol/min)
Number of subjects: 17
Study 8568008 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg daily for 13 days
Number of subjects: 10
Study 8568008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2152777 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fiber (20 mg corn fiber in 4 cookies daily)
Number of subjects: 14
Study 2152777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2152777 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fiber
Number of subjects: 14
Study 25288 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.6 mg
Number of subjects: 0
Study 25288 — intervention group
Group type: COMPARATOR
Intervention: Flurazepam 30 mg
Number of subjects: 0
Study 25288 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 0
Study 31490407 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation based training
Number of subjects: 51
Study 31490407 — intervention group
Group type: COMPARATOR
Intervention: E-learning
Number of subjects: 51
Study 31490407 — intervention group
Group type: COMPARATOR
Intervention: Hands-on training
Number of subjects: 51
Study 29107197 — intervention group
Group type: EXPERIMENTAL
Intervention: PEACH™ intervention
Number of subjects: 37
Study 25440437 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignin peroxidase
Number of subjects: 60
Study 23800112 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Rating Scale (GRS)
Number of subjects: 60
Study 23800112 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklists
Number of subjects: 60
Study 23800112 — intervention group
Group type: EXPERIMENTAL
Intervention: Two raters
Number of subjects: 60
Study 21925909 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA nerve block using lignocaine with vasoconstrictor
Number of subjects: 100
Study 21925909 — intervention group
Group type: COMPARATOR
Intervention: Maxillary infiltration for anesthesia
Number of subjects: 100
Study 19202451 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive therapy or antiviral prophylaxis (valacyclovir or ganciclovir) for 3 months in 60 patients
Number of subjects: 118
Study 19202451 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV viremia with viral load of more than or equal to 2000 copies/mL
Number of subjects: 118
Study 19202451 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy-proven acute rejection
Number of subjects: 118
Study 19202451 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-based immunosuppression
Number of subjects: 118
Study 19202451 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-graft function
Number of subjects: 118
Study 19202451 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor age (per 10-year increase)
Number of subjects: 118
Study 16545748 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment with antiepileptic drugs
Number of subjects: 0
Study 16545748 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment with antiepileptic drugs
Number of subjects: 0
Study 14580077 — intervention group
Group type: EXPERIMENTAL
Intervention: BZD withdrawal (group A)
Number of subjects: 192
Study 14580077 — intervention group
Group type: COMPARATOR
Intervention: BZD continuation (group C)
Number of subjects: 192
Study 14580077 — intervention group
Group type: COMPARATOR
Intervention: BZD continuation (group B)
Number of subjects: 192